Saudi Arabia Approves TMS, Ushering in New Era for Mental Healthcare

RIYADH, Saudi Arabia – May 05, 2026 – In a landmark decision poised to reshape mental healthcare in the Middle East, the Saudi Food & Drug Authority (SFDA) has granted Medical Device Marketing Authorization (MDMA) to neurocare group AG, a German-based leader in mental health technology. The approval allows the company to sell its Transcranial Magnetic Stimulation (TMS) devices within the Kingdom, making it one of the first manufacturers to bring this advanced therapy to Saudi Arabia.

This regulatory milestone introduces a significant, non-invasive, and drug-free alternative for treating conditions like depression. TMS therapy uses targeted magnetic pulses to stimulate nerve cells in the brain regions associated with mood control. For patients who have not responded to traditional treatments, this technology represents a new frontier of hope. The approval signals a major step forward in neurocare's regional expansion and aligns directly with Saudi Arabia's ambitious goals for healthcare modernization.

A Strategic Alignment with Vision 2030

The introduction of TMS technology is not happening in a vacuum. It arrives as Saudi Arabia undergoes a profound societal and economic transformation under its Vision 2030 framework. A key pillar of this vision is the Health Sector Transformation Program, which explicitly prioritizes the adoption of evidence-based, technology-enabled care to improve public health outcomes and create a vibrant healthcare ecosystem.

neurocare's entry into the market is a direct reflection of this national strategy. The Kingdom's healthcare leaders are actively seeking innovative, nonpharmacological solutions to address the growing burden of mental health conditions. TMS fits this need perfectly, offering a high-tech solution that moves away from a sole reliance on medication. Clinical studies have shown that approximately 60% of patients with depression achieve remission with TMS, making it a compelling option for clinicians and health systems aiming for more effective and sustainable outcomes.

“We see tremendous potential across the region for adopting innovative, evidence-based methods such as TMS,” said Tariq El-Titi, Senior Vice President for neurocare in the Middle East and North Africa (MENA) region. “Healthcare leaders in Saudi Arabia are increasingly looking for advanced, nonpharmacological solutions to support patients. We look forward to forming new partnerships across the Kingdom and supporting clinicians as they integrate best-practice TMS therapies powered by German-engineered technology.”

This strategic alignment suggests a strong tailwind for the adoption of neurocare's platform, which combines the TMS technology with digital tools and structured clinical workflows to ensure consistent and personalized care.

Beyond Pills: A New Hope for Patients

For countless individuals, the journey of managing depression is a frustrating cycle of trial and error with antidepressant medications, many of which come with significant side effects and do not work for everyone. TMS offers a fundamentally different approach. As a non-invasive procedure, it is performed while the patient is awake and alert, requires no anesthesia, and allows them to return to their daily activities immediately afterward.

Crucially, the technology comes without the systemic side effects associated with many psychiatric drugs and carries no “black box” warning, the FDA's most stringent caution for prescription medications. This makes it a particularly valuable option for patients who are sensitive to medication or seek drug-free alternatives. The focus on a physical, targeted intervention in the brain may also help destigmatize mental health treatment, reframing it as a neurological condition amenable to technological intervention, much like any other medical issue.

neurocare's model goes beyond simply providing a device. The company emphasizes a “best practice platform” that empowers clinicians to deliver personalized therapy. This integrated approach, which can include psychotherapy and sleep hygiene alongside neuromodulation, aims to treat the whole person, not just the symptoms. “This approval reflects our broader mission to empower clinicians through our best practice platform with our TMS technology first,” stated Thomas Mechtersheimer, Founder and CEO of neurocare group AG. “By combining advanced neuromodulation, digital tools, and integrated processes, we enable providers to deliver more personalized care and achieve better outcomes for patients across the region.”

A Calculated Entry into a Growing Market

neurocare's expansion into Saudi Arabia is a carefully orchestrated move, accelerated by the backing of TVM Capital Healthcare, a private equity investor specializing in emerging markets. The company has been active in the MENA region since early 2024, laying the groundwork through strategic partnerships. Securing SFDA approval positions neurocare as a first mover in a market with immense growth potential.

The company’s competitive advantage lies not just in its German-engineered technology but in its comprehensive, scalable platform. By offering an end-to-end solution—from leading TMS and EEG devices to a cloud-based software platform and a professional training academy—neurocare provides clinics with a turnkey system for adopting a new standard of care. This is particularly appealing to health systems like Saudi Arabia's that are looking for reliable, standardized, and scalable solutions to meet rising demand.

Dr. Helmut Schuehsler, CEO and Chairman of TVM Capital Healthcare, highlighted the importance of this integrated strategy. “With SFDA approval in place, the priority now is execution—embedding TMS within clinical pathways and expanding access beyond traditional hospital settings,” he noted. “We look forward to continuing to work closely with partners and regulators to adapt and scale proven platforms such as neurocare’s to the Kingdom’s needs and support growing mental health demand.”

Navigating Implementation and Future Access

With the regulatory hurdle cleared, the focus now shifts to practical implementation. The success of TMS in Saudi Arabia will depend on several factors, including the training of a skilled clinical workforce, the integration of the therapy into existing mental health pathways, and the establishment of clear reimbursement models to ensure patient access and affordability.

neurocare has indicated that it is actively supporting global efforts to secure reimbursement pathways for TMS, and this experience will be vital in navigating the Saudi Arabian healthcare landscape. The goal is to make this transformative treatment accessible not only in major urban hospitals but also in a wider range of clinical settings, bringing care closer to the communities that need it most.

As regional dynamics continue to highlight the critical importance of resilient healthcare systems, the introduction of locally accessible and personalized mental health solutions is more important than ever. By bringing its proven platform to the Kingdom, neurocare is not just launching a product; it is helping to build a more robust and modern mental wellness infrastructure. This integration of technology and personalized care aims to support both patients and providers, meeting a critical and growing need for effective mental health solutions across the region.